Viagr-ON Hilma Biocare 10tabs /100 mg/tab
€15.00 Original price was: €15.00.€10.00Current price is: €10.00.
Viagr-ON by Hilma Biocare is a potent erectile dysfunction treatment formulated with 100 mg of Sildenafil Citrate per tablet — the same active ingredient used in original Viagra®. It is designed to quickly restore erectile function, improve blood flow, and enhance sexual performance in men facing ED or libido challenges.
With rapid onset and long-standing clinical efficacy, Viagr-ON helps users achieve and maintain a strong, lasting erection during sexual activity. Ideal for occasional use or as needed before intercourse, it delivers fast, reliable results with minimal side effects.
Product Details
- Brand: Hilma Biocare
- Product: Viagr-ON (Sildenafil Citrate)
- Dosage: 100 mg/tablet
- Packaging: 10 tablets
- Form: Oral
- Onset: 30–60 minutes
- Duration: 4–6 hours
Main Benefits
- Fast-acting erectile dysfunction relief
- Enhances erection hardness and duration
- Boosts sexual confidence and performance
- Proven active ingredient (Sildenafil)
- Trusted quality from Hilma Biocare
Suggested Use
- Dosage: 50–100 mg, taken 30–60 minutes before activity
- Max: 100 mg per 24 hours
- Do not combine with nitrates or alcohol
Who Should Use Viagr-ON?
- Men with mild to moderate erectile dysfunction
- Those needing on-demand performance enhancement
- Users recovering from PCT or hormonal suppression
Possible Side Effects
- Headache, flushing, or nasal congestion (mild)
- Visual disturbances (blue tint – dose-related)
- Not suitable for those with cardiovascular issues
Why Choose Viagr-ON by Hilma Biocare?
- Pharma-grade Sildenafil Citrate – 100 mg
- Reliable, consistent erection support
- Ideal for athletes and PCT recovery
- Discreet EU shipping from Steroids EU
Viagr-ON 100 mg by Hilma Biocare is your go-to solution for regaining control, confidence, and peak sexual performance. Whether used occasionally or when needed post-cycle, it’s fast, effective, and trusted. Order now from Steroids EU.

Reviews
There are no reviews yet.